A treatment trade-off based decision aid for patients with locally advanced non-small cell lung cancer

Health Expectations

Volumn 3, Issue 1, 2000, Pages 55-68

  Brundage, Michael D ^a,b,c   Feldman Stewart, Deb ^a,b   Dixon, Peter ^a,b   Gregg, Richard ^b   Youssef, Youssef ^a,b   Davies, Diane ^a,b   Mackillop, William J ^a,b  

^a Radiation Oncology Research Unit   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Carcinoma; Combined modality treatment; Decision support; Non small cell lung

Indexed keywords

ADULT; AGED; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DOCTOR PATIENT RELATION; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PHYSICIAN; PRIORITY JOURNAL;

EID: 0034073161     PISSN: 13696513     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1369-6513.2000.00083.x     Document Type: Conference Paper

References (43)

1. Okawara G, Rusthoven JJ, Newman T, Findlay B, Evans WK. Unresected stage III non-small-cell lung cancer. Cancer Prevention and Control, 1997; 1: 249-259.
2. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced lung cancer. Journal of Clinical Oncology, 1997; 15: 330-340.
3. Brundage MD, Davidson JR, Groome PA, Feldman-Stewart D, Mackillop WJ. Decision analysis in locally advanced non-small cell lung cancer - is it useful? Journal of the National Cancer Institute, 1995; 15: 873-883.
4. Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Social Science and Medicine, 1991; 32: 35-42.
5. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Medical Decision Making, 1996; 16: 262-272.
6. Llewellyn-Thomas HA, Thiel EC, Clark RM. Patients versus surrogates: whose opinion counts on ethics review panels? Clinical Research, 1989; 37: 501-505.
7. O'Connor AM, Boyd NF, Warde P, Stolbach L, Till JE. Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. Journal of Chronic Disease, 1987; 40: 811-818.
8. Kiebert GM, Stiggelbout AM, Leer JH, Kievit J, De Haes JCJM. Test-retest reliabilities of two treatment-preference instruments in measuring utilities. Medical Decision Making, 1993; 13: 133-140.
9. Torrance GW. Utility approach to measuring health-related quality of life. Journal of Chronic Diseases, 1987; 40: 593-600.
10. Mountain CF. A new international staging system for non-small cell lung cancer. Chest, 1986; 89: 225s-233s.
11. Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, 1995; 311: 899-909.
12. Dillman RO, Herndon J, Seagren SL, Eaton WLJ, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. Journal of the National Cancer Institute, 1996; 88: 1210-1215.
13. Anonymous. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. Journal of Clinical Oncology, 1997, 15: 2996-3018.
14. The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clinical Oncology, 1999; 11: S1-S53.
15. Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. British Journal of Cancer, 1986; 54: 661-667.
16. Palmer MJ, O'Sullivan B, Steele R, Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiotherapy and Oncology, 1990; 19: 17-28.
17. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. Journal of Clinical Oncology, 1995; 13: 1904-1911.
18. Green MR. Chemotherapy and radiation in the non-operative management of stage III non-small-cell lung cancer: the right chemotherapy works in the right setting. In: Devita VT. (ed.) Important Advances in Oncology 1993 Philadelphia: J.B. Lippincott, 1993: 125-138.
19. Brundage MD, Mackillop WJ. Locally advanced non-small cell lung cancer: Do we know the questions? Journal of Clinical Epidemiology, 1996; 49: 183-192.
20. Mackillop WJ, Zhou Y, Dixon P, Fu H, Ege G, Ago T. Variation in the management and outcome of non-small cell lung cancer in Ontario. Radiotherapy and Oncology, 1994; 32: 106-115.
21. Holmes-Rovner M. Evaluation standards for patient decision supports. Medical Decision Making, 1995; 15: 2-3.
22. Faden RR, Beauchamp TLA. History and Theory of Informed Consent. New York: N. Y. Oxford University Press, 1986.
23. Cassileth BR, Zupkis RV, Sutton-Smith K, March V. Informed consent - why are its goals imperfectly realized? New England Journal of Medicine, 1980; 302: 896-900.
24. Mackillop WJ, Stewart WE, Ginsburg AD, Stewart SS. Cancer patients' perceptions of their disease and its treatment. British Journal of Cancer, 1988; 58: 355-358.
25. Quirt CF, Mackillop WJ, Ginsburg AD et al. Do doctors know when their patient don't? A survey of doctor-patient communication in lung cancer. Lung Cancer, 1997; 18: 1-20.
26. Brundage MD, Davidson JR, Mackillop W, Feldman-Stewart D, Groome P. Using a treatment-tradeoff methods to elicit preferences for the treatment of locally advanced non-small cell lung cancer. Medical Decision Making, 1998; 18: 256-267.
27. Sause W, Scott C, Taylor S et al. RTOG 88-08 and ECOG 4588: preliminary analysis of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. Journal of the National Cancer Institute, 1995; 8713: 198-205.
28. Gigerenzer G, Hoffrage U. How to improve Bayesian reasoning without instruction: frequency formats. Psychological Review, 1995; 102: 684-704.
29. Degner LF, Sloan JA. Decision making during serious illness: What role do patients really want to play? Journal of Clinical Epidemiology, 1992; 45: 941-950.
30. Hornblow AR, Kidson MA. The visual analogue scale for anxiety: a validation study. Australian and New Zealand Journal of Psychiatry, 1976; 10: 339-341.
31. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ. Whose utilities for decision analysis? Medical Decision Making, 1990; 10: 58-67.
32. McNeil BJ, Weichselbaum RR, Pauker SG. Fallacy of the five-year survival in lung cancer. New England Journal of Medicine, 1978; 299: 1397-1401.
33. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. British Medical Journal, 1998; 317: 775-780.
34. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Policies. Philadelphia: American College of Physicians, 1992.
35. Hammond KR. How convergence of research paradigms can improve research on diagnostic judgement. Medical Decision Making, 1996; 16: 281-287.
36. Hammond KR. Human judgement and social policy; irreducible uncertainty, inevitable error. In: Unavoidable Injustice. New York: Oxford, 1996.
37. Kahneman D, Tversky A. Judgement Under Uncertainty: Heuristics and Biases. Cambridge: Cambridge University Press, 1982.
38. O'Connor AM, Fiset V, De Grasse C, Graham ID, Evans W, Stacey D, Laupacis A, Tugwell MD. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. Journal of the National Cancer Institute, 2000; in press.
39. Goss GD, Logan DM, Newman TE, Evans WK. Use of vinorelbine in non-small cell lung cancer. Cancer Prevention and Contrology, 1997; 1: 28-37.
40. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomized phase III trial. European Journal of Cancer, 1998; 34: 1036-1044.
41. Davidson JR, Brundage MD, Feldman-Stewart D. Cancer treatment decisions: patients' desires for participation and information. Psycho-Oncology, 1999; 8: 511-520.
42. McNeil BJ, Pauker SG, Sox Jr HC, Tversky A. On the elicitation of preferences for alternative therapies. The New England Journal of Medicine, 1982; 306: 1259-1262.
43. O'Connor AM, Boyd NF, Tritchler DL, Kriukov Y, Sutherland H, Till JE. Eliciting preferences for alternative cancer drug treatments: the influence of framing, medium, and rater variables. Medical Decision Making, 1985; 5: 453-463.